Loading
institutionsInstitution
QST Hospital (National Institutes for Quantum Science and Technology)
The world's first carbon-ion therapy hospital (HIMAC, 1994), which established the clinical evidence base for heavy-ion radiotherapy.
Also called: NIRS HospitalHIMACQST病院
Overview
QST Hospital, formerly the National Institute of Radiological Sciences hospital, began treating patients with carbon ions at the Heavy Ion Medical Accelerator in Chiba (HIMAC) in 1994, the first dedicated medical heavy-ion facility. Over three decades it has treated more carbon-ion patients than any other centre, developed hypofractionated protocols for prostate, lung, liver, pancreatic, bone and soft-tissue sarcoma and head and neck tumours, and pioneered scanning beam delivery, respiratory gating and the rotating gantry now used in newer facilities. The institute leads Japan's quantum-scanning carbon-ion programme, radiopharmaceutical research including astatine-211 targeted alpha therapy, and international training for centres in Europe and Asia.
Location
Chiba, JP
Type
research institute
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#241 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
- Carbon-ion therapy (HIMAC)
- Compact carbon-ion technology
- Astatine-211 alpha therapy
- Radiation biology
Similar pages
- Key paperCarbon Ion Therapy: A Modern Review of an Emerging Technology
Shares Carbon-ion synchrotrons and facilities, Carbon-ion therapy.
- InstitutionSeverance Hospital, Yonsei University
Shares Toshiba Energy Systems & Solutions, Carbon-ion synchrotrons and facilities, Carbon-ion therapy.
- CompanyAlpha Tau Medical
Shares Targeted alpha therapy, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Prostate cancer.
- PairingBeta radioligand → alpha radioligand
Shares Alpha vs beta emitters, Targeted alpha therapy, Prostate cancer.
- InstitutionTaipei Veterans General Hospital
Shares Carbon-ion synchrotrons and facilities, Carbon-ion therapy, Hepatocellular carcinoma.
- IdeaRegional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit
- IdeaFund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211
- InstitutionOslo University Hospital, The Norwegian Radium Hospital
Shares Alpha vs beta emitters, Targeted alpha therapy, Sarcomas (soft tissue, bone, GIST), Prostate cancer.